First human trial targets genetic weakness in Tough-to-Treat cancers
NCT ID NCT06710847
Summary
This early-stage study is testing a new oral drug, GSK4418959, for adults with advanced solid tumors that have specific genetic features (called dMMR or MSI-H). The main goals are to find a safe dose, see how the body processes the drug, and check if it can shrink tumors, either by itself or when combined with an immunotherapy drug. The study is for people with cancers like colorectal or endometrial cancer who have few or no other standard treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Denver, Colorado, 80218, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
New York, New York, 10016, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19107, United States
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Shizuoka, 411-8777, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Tokyo, 135-8550, Japan
-
GSK Investigational Site
Amsterdam, 1066 CX, Netherlands
-
GSK Investigational Site
Daegu, 41404, South Korea
-
GSK Investigational Site
Gyeonggi-do, 10408, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Barcelona, 08023, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
Conditions
Explore the condition pages connected to this study.